DARA BioSciences, Inc. (Nasdaq: DARA) (the "Company" or "DARA"), a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today the Company will be presenting at the 6
Annual OneMedForum to be held at the Sir Francis Drake Hotel in San Francisco. David J. Drutz, M.D., CEO and CMO of DARA, will present a corporate overview on Tuesday, January 8
at 11:20 am PST.
The OneMedForum San Francisco conference, which runs concurrently with the J.P. Morgan Annual Healthcare Conference, provides an efficient access to the companies that shape the future of the rapidly changing healthcare landscape with company presentations, panels, and workshops for strategic insights and practical benefits.
Attendees will include institutional investors, high net worth individual investors, senior healthcare and life science executives looking for investment opportunities, market insights, licensing opportunities, acquisitions, joint ventures and strategic partnerships.
Additional information can be found via:
About DARA BioSciences, Inc.
DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA has comprehensive commercial coverage across the national oncology market through a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations (GPOs), retail partners, reimbursement experts, and an industry-leading third-party logistics provider. As part of an integrated national network with annual sales of over $1 billion in cancer therapeutics, DARA has significant commercial scale and capabilities. Its distribution network consists of more than 45,000 retail pharmacies, mail order pharmacies, and long-term care facilities. This provides DARA with established reimbursement and logistics expertise, as well as partnering opportunities with more than 300 sales and marketing personnel uniquely focused on oncology and oncology support products. This comprehensive network of partners is rare if not unique among companies in the oncology supportive care area and provides DARA a strong foundation for product introductions into this underserved market.